Phase 3 Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with swelling in the central part of the eye (called macular edema) linked to diabetic eye disease, whether they have received previous treatment for this condition or not.
- People whose vision in the eye being studied falls within a specific range — not too severely reduced and not near-perfect — as measured by a standard eye chart test at two separate appointments (a screening visit and a baseline visit).
- People who have previously been treated for this eye condition must have received at least one injection of a specific type of eye medication (called anti-VEGF) in the past 12 months, and their most recent injection must have been given at least 12 weeks before the screening visit.
Who may not be able to join:
- People whose vision in their other eye (the eye not being studied) is below a certain level of severity on a standard eye chart test.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 833-393-7646
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Average change in best corrected visual acuity (BCVA)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.